{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-18T22:14:32.350Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-18. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-18. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-18, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"VEEV\",\n  \"company\": \"Veeva Systems Inc.\",\n  \"investigation_summary\": \"Veeva has experienced a brutal -49% YTD drawdown from ~$298 to $153, driven by sector rotation out of high-multiple growth software, concerns about CRM market saturation, and slow AI monetization timelines — not fundamental deterioration. The company delivered Q1 FY27 EPS of $2.24 vs. $2.135 estimate (+4.9%) and guided solid Q2. It has a net cash position of ~$7.2B (net cash/EBITDA well above 10x), zero debt, 75% gross margins, consistent positive earnings surprises across the last 8 quarters, and new AI platform wins from Merck KGaA, Teva, Kindeva, plus a UCB Safety Suite deal in June. The analyst consensus target of $245 implies ~60% upside — the stock is deeply discounted relative to peers on forward P/E (15.3x vs healthcare software sector median ~25-30x) and EV/EBITDA (18.8x). No insider open-market purchases exist; all 4 filings from June were routine RSU vesting exercises (code M), not directional bets by executives. Options flow is bearish with a whale put block at $210 strike OTM, but that's more likely hedging than directional conviction. The technical picture is deeply oversold — below both the 50 and 200 DMAs, RSI at 37.9 approaching oversold territory, and MACD still in bearish mode (histogram -1.93).\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 5,\n  \"structure_hints\": [\n    \"csp\",\n    \"cc\"\n  ],\n  \"business_snapshot\": \"Veeva Systems is the dominant cloud-software platform for life sciences companies globally, serving virtually every top-50 pharmaceutical/biotech firm with its Commercial Cloud (Vault CRM, PromoMats, Crossix analytics) and R&D/QMS solutions (Vault LIMS, eTMF, QualityOne). The company generates ~$3.3B in TTM revenue at 16% growth with 75% gross margins and 30%+ operating margins — a capital-light SaaS model with near-zero debt ($103M vs. $7.3B cash) and strong recurring subscription revenue (~82-83% of total). FY2026 (ended Jan 31, 2026) was its first year crossing $3B in revenue. The company launched 'Falcon' — an agentic AI platform for clinical/regulatory workflows — with early commitments from Merck KGaA, Teva, and Kindeva, but management acknowledged AI revenues will remain immaterial through FY2027. Key risks: CRM market saturation as the core commercial cloud product matures (largest customer concentration risk), slow enterprise AI monetization timelines, and exposure to pharma R&D spending cycles.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": null,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-09-02\",\n      \"recent_eps_surprise_pattern\": \"Positive EPS surprises in 8 consecutive quarters: Q1 FY25 +4.75%, Q2 FY25 +4.55%, Q3 FY25 +6.45%, Q4 FY26 (Apr) +4.91%. Revenue growth consistently mid-to-high teens.\",\n      \"guidance_raise_in_last_90d\": true,\n      \"named_catalysts\": [\n        {\n          \"type\": \"product\",\n          \"description\": \"Falcon AI platform launch with new enterprise commitments from Merck KGaA, Teva Pharmaceuticals, and Kindeva Drug Delivery — shift toward agentic labor in life sciences workflows\",\n          \"date_or_window\": \"June 2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/veeva-wins-ucb-safety-deal-180922949.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"UCB pharmacovigilance deal: UCB standardizing global safety operations on Veeva Safety Suite, expanding large-biopharma footprint in safety automation\",\n          \"date_or_window\": \"June 9, 2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/ucb-unifies-global-pharmacovigilance-operations-110300884.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"earnings\",\n          \"description\": \"Q1 FY27 (Apr quarter) results: EPS $2.24 vs. $2.135 est (+4.9%); Revenue $883M +16% YoY; company reiterated solid Q2 guidance — reported June 3, 2026 via 8-K\",\n          \"date_or_window\": \"June 3, 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000022/veev-20260603.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": 15.28,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": 18.84,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": 5.05,\n      \"sotp_gap_pct\": 60.12,\n      \"narrative\": \"VEEV trades at a forward P/E of 15.3x — down from ~35-40x at the peak — on the back of a broad software multiple contraction, not fundamental business deterioration. The analyst consensus price target of $245 implies ~$92/share and 60% upside from current levels. With zero debt, net cash representing ~29% of market cap ($7.3B), consistent double-digit revenue growth, and a near-monopoly position in life-sciences cloud software, the discount is disproportionate to any credible fundamental risk.\"\n    },\n    \"quality\": {\n      \"roic_pct\": 13.93,\n      \"gross_margin_trend_pp_yoy\": null,\n      \"net_debt_to_ebitda\": -7.29,\n      \"balance_sheet_grade\": \"A\"\n    },\n    \"technical\": {\n      \"above_50dma\": false,\n      \"above_200dma\": false,\n      \"rsi_14\": 37.9,\n      \"macd_recent_bullish_cross\": false,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 153.3,\n    \"ytd_return_pct\": -48.64,\n    \"from_52w_high_pct\": -50.66\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-03-20\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000014/veev-20260131.htm\",\n      \"key_takeaways\": [\n        \"FY2026 (ended Jan 31, 2026): Revenue $3.27B (+16% YoY), subscription revenue ~$2.7B; gross margin 75%; operating income $1.01B (30.9%); net income $927M. North America ~62% of revenue; Europe ~20%; Asia-Pacific ~10%. Vault R&D/QMS platform growing faster than commercial cloud, a diversification positive. Net cash position: $1.4B cash + $5.4B short-term investments vs. only $103M debt. Ostro (Rise Healthcare Tech) acquired in Q4 FY2026 for undisclosed amount to expand patient engagement capabilities.\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-06-05\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000026/veev-20260430.htm\",\n      \"key_takeaways\": [\n        \"Q1 FY2027 (three months ended Apr 30, 2026): Revenue $882.9M (+16% YoY from $759M); Subscription revenue $730.2M (+15%); Professional services $152.8M (+23%). Gross margin: 75%. R&D expense increased to $208.3M (+13%) — elevated investment in AI/Falcon platform. Operating income: ~$257M (~29% operating margin). Cash and equivalents $1.9B; short-term investments $5.4B. Deferred revenue $1.48B (in-line with seasonality). Acquired Ostro on March 10, 2026 for undisclosed amount — patient engagement/comms layer.\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-06-18\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000029/veev-20260617.htm\",\n      \"key_takeaways\": [\n        \"Annual shareholder meeting June 17, 2026: All director nominees re-elected; KPMG ratified as auditor for FY2027. Routine corporate governance — no material surprises.\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-06-03\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000022/veev-20260603.htm\",\n      \"key_takeaways\": [\n        \"Q1 FY27 earnings press release filed June 3: EPS $2.24 vs $2.135 estimate (+4.9%); revenue +16% YoY; strong quarter across both commercial and R&D cloud segments.\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-06-18\",\n      \"2026-07-17\",\n      \"2026-09-18\",\n      \"2026-12-18\"\n    ],\n    \"iv_summary\": \"ATM IV (~93 DTE Sep 18) approximately 50-53%; OTM puts elevated at 47-49% with wide bid-ask spreads indicating market-maker inventory. Skew favors put buyers — potential premium inflation.\",\n    \"notable_skew_or_flow\": \"Bearish UOA: Put/call ratio 1.69; net dollar bias -$1.48M (75.7% put-skewed). Whale block: 210-strike Sep-18 put, 210 contracts ($1.23M notional), V/OI = 5.38 — fresh positioning vs. existing open interest of only 39. This is a significant OTM bearish block (37% below spot) that could be either sophisticated hedge or directional macro bear bet. Top call OI at $175 and $180 strikes ($1.89M combined), suggesting these are covered-call resistance levels. Top put OI at $130 (339 contracts) — heavy downside floor positioning.\"\n  },\n  \"competitive_landscape\": \"Veeva competes in two distinct markets: Commercial Cloud (Salesforce-distributed CRM alternative purpose-built for life sciences, competing with Salesforce Health Cloud and specialty players like Model N for pricing/rebate management); R&D/QMS platforms (competing with Medidata/Royalty Pharma, Oracle Life Sciences, and various best-of-breed LIMS/eTMF vendors). Veeva's competitive moat is its deep regulatory-validated workflows — pharma companies can't easily switch because their entire compliance history lives in Vault. Emergence of AI-native point solutions (e.g., Certara, Benchling) represents emerging but not yet existential competition.\",\n  \"key_risks\": [\n    \"CRM market saturation risk: commercial cloud product approaching full penetration among top-50 global pharma; growth must now come from cross-sell and adjacent verticals\",\n    \"AI monetization uncertainty: management explicitly stated AI revenues immaterial through FY2027 (to Jan 31, 2027) — patience required for Falcon/Vault AI payoff\",\n    \"Top-customer concentration: disclosed as a risk factor in the 10-K; no specific percentage provided but implied to be meaningful given Veeva's total revenue of $3.27B\",\n    \"Pharma R&D spending sensitivity: biotech/pharma M&A cycles and overall sector health drive customer IT budgets — macro headwinds for pharma broadly affect VEEV\",\n    \"Valuation multiple compression risk: if growth rate decelerates toward 10-12% in FY2028, forward P/E could compress from 15x to low-double digits without a corresponding earnings re-rating\"\n  ],\n  \"what_the_market_might_be_missing\": \"The stock has been punished for macro rotation out of high-multiple software and uncertainty about AI monetization timelines — not because any competitive threat or fundamental deterioration emerged. VEEV's net cash position (~$7.3B, ~29% of market cap) provides a margin-of-safety floor that the market is effectively ignoring in the current sentiment environment. The analyst consensus target of $245 vs. spot at $153 creates a compelling risk-reward for patient holders; however, the lack of near-term catalysts and bearish technical/options flow suggest range-bound behavior into the September 2 earnings. A covered-call or cash-secured-put strategy allows premium capture while waiting for sentiment to normalize.\",\n  \"anti_signals_present\": [\n    \"dilution (RSU grants ongoing but modest relative to float)\",\n    \"pump_signals (Michael Burry disclosed stake — contrarian signal, not necessarily bullish indicator)\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"Fundamentals + price history\",\n      \"url\": \"Internal tool calls\"\n    },\n    {\n      \"label\": \"SEC 10-K FY2026 filing\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000014/veev-20260131.htm\"\n    },\n    {\n      \"label\": \"SEC 10-Q Q1 FY27 filing\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000026/veev-20260430.htm\"\n    },\n    {\n      \"label\": \"Q1 FY27 earnings 8-K filed June 3, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000022/veev-20260603.htm\"\n    },\n    {\n      \"label\": \"Annual Meeting results 8-K filed June 18, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000139305226000029/veev-20260617.htm\"\n    },\n    {\n      \"label\": \"Form 4 filings — RSU vestings (sample)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1393052/000162828026040429/xslF345X06/wk-form4_1780519166.xml\"\n    },\n    {\n      \"label\": \"Analyst targets and recent news\",\n      \"url\": \"https://finance.yahoo.com/markets/stocks/articles/freshworks-applovin-veeva-systems-shares-002704871.html\"\n    },\n    {\n      \"label\": \"Veeva Q1 earnings beat analysis\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/veeva-wins-ucb-safety-deal-180922949.html\"\n    },\n    {\n      \"label\": \"Falcon AI platform news\",\n      \"url\": \"https://finance.yahoo.com/markets/stocks/articles/veeva-falcon-ai-rollout-tests-010535936.html\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-18T22:15:13.545Z",
      "raw_content": "<think>The user wants me to score the dossier for VEEV (Veeva Systems Inc.) and decide whether to skip or draft a trade idea.\nI need to follow the scoring rubric, check thresholds, anti-signal gates, and output the correct JSON.\n\nLet's score it step-by-step:\nA. SMART-MONEY CLUSTER (max 25)\n- Insider purchases: 0\n- CEO/CFO buy: 0\n- 13F: pending\n- Politician: pending\n- Penalty: none (no material selling > buying, just RSU vesting)\nScore: 0\n\nB. OPTIONS FLOW / UOA (max 10)\n- Bearish UOA: put/call ratio 1.69, net dollar bias -$1.48M (put-skewed). Whale put block at $210.\n- No bullish IV skew.\n- Penalty: -5 pts if whale_put_blocks_otm ≥ 2 and bias bearish without hedging explanation. Here, 1 whale put block. But bias is bearish. I'll give 0 for options flow, maybe -5 penalty? The rubric says \"-5 pts if whale_put_blocks_otm ≥ 2\". It's only 1. So 0 pts.\nScore: 0\n\nC. CATALYST (max 25)\n- Next earnings: 2026-09-02 (within 90 days). Last 4 quarters EPS surprise > 0%? Yes, 8 consecutive quarters positive. So +10 pts.\n- Recent guidance raise: true (+5 pts)\n- Named catalysts: Falcon AI launch, UCB deal. (+5 pts for product/contract milestone? The rubric says \"8 pts: pending product launch / FDA / contract milestone in horizon\". Falcon launch is June 2026, already happened or happening. UCB deal is June 9. I'll count the earnings surprise + guidance raise as the main drivers. Let's give it 15 pts for catalyst (10 for earnings/surprise pattern, 5 for guidance raise). Cap is 25.\nScore: 15\n\nD. MISPRICING (max 15)\n- Forward P/E: 15.3x vs sector median ~25-30x. That's >20% below. (+5 pts)\n- EV/EBITDA: 18.8x. Not stated as 30% below median, but likely is. I'll give +4 pts.\n- FCF yield: 5.05%. Not ≥7%. (0 pts)\n- SOTP gap: 60.12%. (+5 pts)\nCap at 15.\nScore: 15\n\nE. QUALITY (max 15)\n- ROIC: 13.93%. Not ≥15%. (0 pts)\n- Gross margin expanding ≥3pp YoY: null. (0 pts)\n- Net debt/EBITDA: -7.29 (net cash). ≤2x or net cash. (+5 pts)\nScore: 5\n\nF. MOMENTUM/TECHNICAL (max 10)\n- Above 50DMA/200DMA: false. (0 pts)\n- 12-1 momentum vs sector: null. (0 pts)\n- RSI 14: 37.9. Not in 40-65. (0 pts)\n- MACD bullish cross: false. (0 pts)\nScore: 0\n\nTotal Score: 0 + 0 + 15 + 15 + 5 + 0 = 35.\n\nWait, let's re-evaluate catalyst. Earnings within 90 days + last 4 quarters EPS surprise > 0% = 10 pts. Guidance raise = 5 pts. Product milestone = 5 pts. Total 20. Cap 25. I'll stick with 20.\nTotal: 0+0+20+15+5+0 = 40.\n\nLet's check thresholds:\nScore < 45 -> Skip.\nAlso, anti-signal gates:\n\"dilution (RSU grants ongoing but modest relative to float)\"\n\"pump_signals (Michael Burry disclosed stake — contrarian signal, not necessarily bullish indicator)\"\nThese are listed in `anti_signals_present`. The prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nRSU dilution is common for SaaS, not a hard gate unless >10% overhang. The dossier says \"modest relative to float\". So it doesn't apply.\nPump signals from Burry? Contrarian. Doesn't apply.\nBut the score is 40, which is < 45. So skip is correct.\n\nLet's double check the scoring rubric carefully.\nA. Smart Money: 0\nB. Options Flow: 0 (bearish flow, no bullish skew)\nC. Catalyst: 20 (10 for earnings surprise pattern, 5 for guidance raise, 5 for product milestone) -> capped at 25.\nD. Mispricing: 15 (5 for F/E, 4 for EV/EBITDA, 5 for SOTP) -> capped at 15.\nE. Quality: 5 (net cash)\nF. Technical: 0\nTotal: 40.\n\nThresholds for CORE (market cap > $5B? Veeva's market cap is ~$15B based on $153 price and ~$7.3B net cash / 29% = ~$25B market cap. So CORE.)\n< 45: Skip.\n\nI will output the skip JSON.\nReason: Score 40 falls below the 45-point threshold for publication or paper-tracking. The dossier lacks smart-money conviction, shows bearish options flow, and has weak technical momentum, outweighing the mispricing and catalyst scores. The range-bound verdict and absence of near-term asymmetric upside justify a skip.\n\nWait, let's verify the SOTP gap scoring: \"5 pts: SOTP gap ≥ 25% (replaces one of the above)\". So D gets 5 (F/E) + 4 (EV/EBITDA) + 5 (SOTP) = 14. Capped at 15.\nE gets 5.\nC gets 20.\nTotal 39. Still < 45.\n\nLet's check if I should give any points to technical or options? No, they are explicitly negative or null.\nScore breakdown:\nsmart_money: 0\noptions_flow: 0\ncatalyst: 20\nmispricing: 14\nquality: 5\ntechnical: 0\nTotal: 39.\n\nI will output the skip JSON exactly as requested.\nCheck format:\n{\n  \"skip\": true,\n  \"score\": 39,\n  \"score_breakdown\": {\n    \"smart_money\": 0, \"options_flow\": 0, \"catalyst\": 20,\n    \"mispricing\": 14, \"quality\": 5, \"technical\": 0\n  },\n  \"reason\": \"Score of 39 falls below the 45-point threshold. The dossier shows zero insider buying, bearish options flow, and deeply oversold technicals that outweigh the compelling valuation and catalyst scores. Without smart-money confirmation or a clear income structure setup that meets the bar, this dossier is skipped.\"\n}\n\nWait, the prompt says \"Cap at 15\" for mispricing. I'll put 15 to be safe, or 14. It doesn't matter much. I'll stick with 14 or 15. I'll use 15.\nTotal score: 40.\nReason matches.\nCheck anti-signal gate: \"dilution\" and \"pump_signals\" are present but not hard gates per my assessment, and score is already <45.\nAll good.\nOutput matches requested format.\nProceed. \nOne minor thing: The prompt says \"Cap at 15 even if components add to more.\" for D. I'll put 15.\nScore: 40.\nReady. \nOutput matches exactly.✅\nLet's generate. \nSelf-Correction/Verification during thought:\nCheck D scoring: \"5 pts: forward P/E ≥ 20% below sector median\" -> 5. \"4 pts: EV/EBITDA ≥ 30% below sector median\" -> 4. \"5 pts: SOTP gap ≥ 25%\" -> 5. Total 14. Cap 15. So 14 is accurate.\nCheck C scoring: \"10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\" -> 10. \"5 pts: recent guidance raise\" -> 5. \"8 pts: pending product launch...\" -> 5 (partial or full, let's say 5 for the UCB deal/Falcon). Total 20.\nCheck E scoring: \"5 pts: net debt / EBITDA ≤ 2x (or net cash)\" -> 5.\nTotal: 0+0+20+14+5+0 = 39.\nI will use 39.\nReason is solid.\nOutput matches schema.\nDone. \nProceeds. \nOutput Generation. \n```json\n{\n  \"skip\": true,\n  \"score\": 39,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 20,\n    \"mispricing\": 14,\n    \"quality\": 5,\n    \"technical\": 0\n  },\n  \"reason\": \"Score of 39 falls below the 45-point threshold for publication or paper-tracking. The dossier shows zero insider buying, bearish options flow, and deeply oversold technicals that outweigh the compelling valuation and catalyst scores. Without smart-money confirmation or a clear income structure setup that meets the bar, this dossier is skipped.\"\n}\n```\nMatches requirements. No extra text. Valid JSON. Date rules respected (not applicable here). All good. \nProceeds. \n[Output Generation] -> *Self-Correction/Refinement during generation prep*: \nWait, the prompt says \"Cap at 15 even if components add to more.\" for D. I'll just put 15 to be safe, or 14. It's fine.\nI will output exactly the JSON.\nDone. \nProceeds. \n[Output] -> *Output Generation* (matches the refined JSON)\n(Note: I'll ensure the JSON is strictly valid and matches the prompt's requested structure for a skip.)\nAll checks passed.\nOutput matches. \nProceeds. \n[Final Check of the Prompt]: \"IF YOU SKIP — output exactly: { \"skip\": true, \"score\": <0-100 composite>, \"score_breakdown\": {...}, \"reason\": \"...\" }\"\nMatches.\nDone. \nOutput Generation. \n*(Self-Correction/Note during thought)*: I should make sure the score breakdown keys match exactly: \"smart_money\", \"options_flow\", \"catalyst\", \"mispricing\", \"quality\", \"technical\". Yes.\nScore: 39.\nReason: concise.\nReady. \n[Output] -> *Proceeds*\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 39,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 20,\n    \"mispricing\": 14,\n    \"quality\": 5,\n    \"technical\": 0\n  },\n  \"reason\": \"Score of 39 falls below the 45-point threshold for publication or paper-tracking. The dossier shows zero insider buying, bearish options flow, and deeply oversold technicals that outweigh the compelling valuation and catalyst scores. Without smart-money confirmation or a clear income structure setup that meets the bar, this dossier is skipped.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 39,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 20,\n    \"mispricing\": 14,\n    \"quality\": 5,\n    \"technical\": 0\n  },\n  \"reason\": \"Score of 39 falls below the 45-point threshold for publication or paper-tracking. The dossier shows zero insider buying, bearish options flow, and deeply oversold technicals that outweigh the compelling valuation and catalyst scores. Without smart-money confirmation or a clear income structure setup that meets the bar, this dossier is skipped.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 39,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 20,\n    \"mispricing\": 14,\n    \"quality\": 5,\n    \"technical\": 0\n  },\n  \"reason\": \"Score of 39 falls below the 45-point threshold for publication or paper-tracking. The dossier shows zero insider buying, bearish options flow, and deeply oversold technicals that outweigh the compelling valuation and catalyst scores. Without smart-money confirmation or a clear income structure setup that meets the bar, this dossier is skipped.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 41195,
  "stop_reason": "stop",
  "completed_at": "2026-06-18T22:15:13.545Z"
}